No Data
No Data
No Data
No Data
No Data
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vertex Pharmaceuticals Inc's (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite
BenzingaApr 27 02:34
Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk
1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a res
WSJApr 24 02:54
TD Cowen: Downgraded Alpine Immune Sciences (ALPN.US) rating from buy to hold.
TD Cowen: Downgraded Alpine Immune Sciences (ALPN.US) rating from buy to hold.
Zhitong FinanceApr 16 18:51
TD Cowen Downgrades Alpine Immune Sciences to Hold
TD Cowen analyst Boris Peaker downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Buy to Hold.
BenzingaApr 16 18:49
Alpine Immune Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 — TD Cowen Downgrades Buy → Hold 04/12/2024 0.9% Leerink Partners $42 → $65 Downgrades Outperf
BenzingaApr 16 18:44
Could This Stock Be the Next Biotech Buyout?
Yahoo FinanceApr 13 17:29
No Data
No Data